JP2021535896A - 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体 - Google Patents

気管支肺異形成症の治療における抗Ｆｌｔ−１抗体 Download PDF

Info

Publication number
JP2021535896A
JP2021535896A JP2020571610A JP2020571610A JP2021535896A JP 2021535896 A JP2021535896 A JP 2021535896A JP 2020571610 A JP2020571610 A JP 2020571610A JP 2020571610 A JP2020571610 A JP 2020571610A JP 2021535896 A JP2021535896 A JP 2021535896A
Authority
JP
Japan
Prior art keywords
flt
antibody
antigen
binding fragment
bpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020571610A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019246521A5 (https=
JP2021535896A5 (https=
Inventor
デニス キーフ，
ジェニファー ボスコ，
スティーブン アブマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2021535896A publication Critical patent/JP2021535896A/ja
Publication of JPWO2019246521A5 publication Critical patent/JPWO2019246521A5/ja
Publication of JP2021535896A5 publication Critical patent/JP2021535896A5/ja
Priority to JP2023099270A priority Critical patent/JP2023108031A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2020571610A 2018-06-22 2019-06-21 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体 Pending JP2021535896A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023099270A JP2023108031A (ja) 2018-06-22 2023-06-16 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862688541P 2018-06-22 2018-06-22
US62/688,541 2018-06-22
PCT/US2019/038470 WO2019246521A1 (en) 2018-06-22 2019-06-21 Anti-flt-1 antibodies in treating bronchopulmonary dysplasia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023099270A Division JP2023108031A (ja) 2018-06-22 2023-06-16 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体

Publications (3)

Publication Number Publication Date
JP2021535896A true JP2021535896A (ja) 2021-12-23
JPWO2019246521A5 JPWO2019246521A5 (https=) 2022-06-28
JP2021535896A5 JP2021535896A5 (https=) 2022-06-28

Family

ID=67211919

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020571610A Pending JP2021535896A (ja) 2018-06-22 2019-06-21 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体
JP2023099270A Pending JP2023108031A (ja) 2018-06-22 2023-06-16 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023099270A Pending JP2023108031A (ja) 2018-06-22 2023-06-16 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体

Country Status (5)

Country Link
US (1) US20210261672A1 (https=)
EP (1) EP3810652A1 (https=)
JP (2) JP2021535896A (https=)
CN (1) CN113260628A (https=)
WO (1) WO2019246521A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026072909A2 (en) * 2024-09-27 2026-04-02 Amgen Inc. Flt1 binding proteins and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164579A1 (en) * 2015-04-07 2016-10-13 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
JP2018515442A (ja) * 2015-04-07 2018-06-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010206543A1 (en) * 2009-01-26 2011-07-07 Intermune, Inc. Methods for treating acute myocardial infarctions and associated disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164579A1 (en) * 2015-04-07 2016-10-13 Shire Human Genetic Therapies, Inc. Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
JP2018515442A (ja) * 2015-04-07 2018-06-14 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド 気管支肺異形成症の治療における抗Ｆｌｔ−１抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HYPERTENSION, vol. 68, JPN6023010971, 2016, pages 678 - 687, ISSN: 0005015066 *

Also Published As

Publication number Publication date
EP3810652A1 (en) 2021-04-28
CN113260628A (zh) 2021-08-13
JP2023108031A (ja) 2023-08-03
WO2019246521A1 (en) 2019-12-26
US20210261672A1 (en) 2021-08-26

Similar Documents

Publication Publication Date Title
JP5529536B2 (ja) 虚血性障害又は血管不全の治療におけるＤｌｌ４アンタゴニストの使用
BR112021010920A2 (pt) Método de tratamento de condições neutrofílicas
AU2024227035A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
US20200362041A1 (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
EA029860B1 (ru) Фармацевтическая композиция и способы лечения заболеваний мочеполовой системы
CN119548617B (zh) 重组xvii型人源化胶原蛋白的新用途
KR20150109386A (ko) 뒤시엔느 근위축증의 치료에서의 항-Flt-1 항체
CN106573012B (zh) 平均分子量低于10000Da的硫酸葡聚糖用于诱导受试者中的血管新生的用途
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
KR20210044742A (ko) 건선 치료용 조성물 및 방법
JP2023113883A (ja) 小児患者のための生物薬剤組成物及び方法
JP2023108031A (ja) 気管支肺異形成症の治療における抗Ｆｌｔ－１抗体
CA2982815C (en) Anti-flt-1 antibodies in treating bronchopulmonary dysplasia
BR112017021416B1 (pt) Uso de um anticorpo anti-flt-1 ou seu fragmento de ligação ao antígeno

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20210728

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220620

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220620

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230317

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230317

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231010